首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1821507

抗體發現市場 - 服務和平台:2035年前的產業趨勢和全球預測 - 抗體發現階段，各方法，性質，各抗體類型，各治療領域，各終端用戶，各地區

Antibody Discovery Market - Focus on Services and Platforms: Industry Trends and Global Forecasts, till 2035 - Distribution by Antibody Discovery Step, Method, Nature of, Type of Antibody, Therapeutic Area, End-user and Geographical Regions

出版日期: 2025年09月24日 | 出版商:

Roots Analysis | 英文 607 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

抗體發現市場：概覽

預計到 2035 年，抗體發現市場規模將從目前的 24 億美元增長至 66 億美元，預測期內複合年增長率達 10.5%。

本市場細分按以下參數細分了市場規模與機會：

抗體發現步驟

標靶藥物生成
先導化合物篩選
先導化合物優化

抗體發現方法

基於雜交瘤的方法
噬菌體展示文庫方法
基因改造動物方法
基於酵母展示的方法方法
基於單細胞的方法
其他

抗體的性質

人抗體
人體化抗體
嵌合抗體
鼠標抗體

治療領域

腫瘤學的疾病
免疫疾病
感染疾病領域
循環系統疾病
神經疾病
其他的疾病

抗體類型

單株抗體
二特異性抗體
抗體藥物複合體
免疫複合體
其他的抗體

終端用戶

公司內部部門
受託研究機構

地區

北美
歐洲
亞太地區
中東·北非
南美

抗體發現服務市場成長與趨勢

抗體在辨識和中和外來物質方面發揮著至關重要的作用。由於其特異性高、安全性好等諸多優勢，這些分子已成為極具前景的選擇，尤其是在治療癌症、自體免疫疾病和傳染病方面。抗體目前是最大的生物製劑類別，迄今已有超過80個分子獲得批准，超過200個分子處於臨床前/發現階段。

儘管已獲得多項批准，但在設計、生產和臨床應用的多個階段仍存在各種尚未解決的挑戰。鑑於現代藥物開發的複雜性，許多公司正將外包作為優化研究工作的策略解決方案。這種預期轉變的原因多種多樣，包括縮短研發週期、降低與試驗失敗相關的財務風險以及加速工作流程。目前，約有 125 家公司提供各種抗體發現服務。

人工智慧和機器學習的進步是該領域的關鍵，它們有助於預測抗體-抗原相互作用，並提高先導化合物的鑑定效率。

在這些發展的推動下，抗體發現市場預計將在未來幾年蓬勃發展，惠及眾多持續推動該領域創新的利害關係人。

本報告深入探討了抗體發現市場的現狀，並識別了該行業的潛在成長機會。報告的主要發現包括：

目前，全球近 125 家公司聲稱提供客製化服務以支援抗體發現相關活動，其中大多數公司位於北美。
相當大比例的服務提供者（88%）提供抗體發現服務，其中57%採用基於文庫的方法來支持治療性抗體的發現。
目前，市面上有近265種抗體發現技術，透過加速高特異性抗體的鑑定和開發，徹底改變了抗體發現領域。
其中45%支持單株抗體的發現。

利害關係人正積極增強現有能力，提升競爭力，以在抗體發現服務領域取得優勢。
為了獲得競爭優勢，利害關係人正在積極創新和開發新的抗體發現技術/平台，以支持多種類型抗體的發現。
60% 的合作協議是在 2021 年之後簽署的，其中技術/產品授權協議成為最主要的合作模式。
由於預期獲得豐厚回報，許多公私投資者自 2020 年以來已投資了相當於 360 億美元的資金。

由於對標靶生物製劑和個人化醫療的需求不斷增長，預計到 2035 年，抗體發現市場將以 10.1% 的複合年增長率 (CAGR) 增長。
預計採用基於雜交瘤方法的服務提供者將獲得最大的市場機會。按抗體類型劃分，單株抗體細分市場預計將顯著成長。

從長遠來看，單株抗體發現平台有望成為主要貢獻者，預計亞太地區將經歷最快的成長。

抗體發現服務市場的主要細分市場

根據抗體發現步驟，抗體發現市場的服務細分市場分為先導化合物優化、先導化合物篩選和標靶化合物發現。目前，先導化合物優化細分市場佔了整體市場佔有率的大部分（61%）。值得注意的是，先導化合物優化能夠篩選出在親和力、穩定性和特異性方面均表現優異的高品質候選抗體，從而提高臨床成功的可能性。

抗體發現服務市場依發現方法分為：基於雜交瘤、基於噬菌體展示文庫、基於基因改造動物、基於酵母展示、單細胞和其他。

目前，基於雜交瘤的方法佔市場主導地位（35%）。其高效性和低複雜度使其在抗體發現領域越來越受歡迎。此外，基於雜交瘤的方法對於開髮用於治療癌症、自體免疫疾病和傳染病的治療性單株抗體至關重要。

依據抗體特性，抗體發現市場服務區隔市場分為人源抗體、人源化抗體、嵌合抗體和鼠源抗體。人源抗體細分市場目前佔全球服務市場的最大佔有率（53%）。人源抗體的諸多優勢，例如較低的免疫原性和單株抗體在人體內的血清半衰期延長，使其佔了較高的市場佔有率。

全球抗體發現服務市場規模依治療領域細分，包括腫瘤學、免疫學、傳染病、心血管疾病、神經系統疾病和其他疾病。目前，腫瘤學細分市場佔市場主導地位（48%）。這是由於全球腫瘤疾病發生率不斷上升，迫切需要開發和生產有效的治療方法，包括基於抗體的治療方法。

依抗體類型細分，全球抗體發現服務市場細分為單株抗體、雙特異性抗體和免疫偶聯物。目前，單株抗體（60%）佔市場主導地位，這一趨勢在未來不太可能改變。這是因為單株抗體具有高度的特異性、一致性和可重複性，使其成為標靶治療的理想選擇。此外，單株抗體已被證明在治療多種疾病方面非常有效，包括癌症、自體免疫疾病和傳染病。

同樣，依抗體類型，全球技術/平台市場細分為單株抗體、雙特異性抗體、抗體-藥物偶聯物和其他抗體。

技術/平台市場將成為預測期內成長最快的細分市場。

依最終用戶細分，抗體發現市場的技術/平台市場細分為兩大不同的終端用戶：內部參與者和合約研究組織。內部製造商細分市場 (98%) 佔最大市場佔有率。這是因為內部公司擁有專業團隊、豐富的內部資源以及對智慧財產權的控制，這使得他們能夠簡化藥物發現流程並保持競爭優勢。

此細分市場揭示了全球服務市場規模按地區分佈的情況，包括北美、歐洲、亞太地區、中東和北非以及拉丁美洲。我們估計，由於大型製藥公司的存在、完善的監管框架以及各種技術進步，北美（50%）今年將佔大部分市場佔有率。同時，亞太地區預計在預測期內將實現13.3%的複合年增長率的健康成長。

同樣，技術/平台市場細分為多個區域，包括北美、歐洲和亞太地區。我們的預測表明，鑑於總部位於北美的技術和平台提供商簽署的技術許可和整合協議數量最多，北美將佔整個市場的大多數佔有率。

此外，預計亞太市場在未來將以更快的速度成長（複合年增長率為9.30%）。

初步研究概述

本研究中提出的觀點和見解受到與市場中多個利害關係人討論的影響。本研究報告也包含與產業利害關係人（按資歷排序）的詳細訪談記錄。

美國，小規模企業，執行長兼最高科學負責人
德國，小規模企業，執行長兼總經理
美國，小規模企業，執行長
美國，大企業，原執行長
美國，中堅企業，執行長
美國，中堅企業，執行長
美國，中堅企業，原執行長
美國，大企業，原最高科學負責人
美國，中堅企業，社長兼最高執行負責人
美國，中堅企業，創業者兼技術長
美國，中堅企業，創業者兼社長
美國，中堅企業，商業服務部門副總統
美國，中堅企業，上級副社長
加拿大，大企業，共同創立者兼新興科學技術擔當董事
印度，小企業，共同成立者兼董事
美國，大企業，原網站董事
美國，小企業，事業開發管理者

抗體發現服務市場上參與企業案例

Ablexis
Abwiz Bio
Abzena
Aragen Life Sciences
BIOTEM
ChemPartner
Creative Biolabs
DetaiBio
FairJourney Biologics
Fusion Antibodies
Genmab
Harbour BioMed
Immunome
ImmunoPrecise Antibodies
Integral Molecular
Isogenica
ProteoGenix
Syd Labs
Viva Biotech
WuXi Biologics

抗體發現服務市場研究報告

抗體發現服務市場規模及機會分析：本報告按主要細分市場深入分析了全球抗體發現市場：[A] 抗體發現步驟，[B] 抗體發現方法，[C] 抗體特性，[D] 治療領域，[E] 抗體類型，[F] 地區。
抗體發現技術/平台市場：本報告按主要細分市場深入分析了全球抗體發現市場：[A] 抗體類型，[B] 最終用戶類型，[C] 地區。
市場模式：基於若干相關參數對參與抗體發現市場的公司進行深入評估，例如 A] 成立年份、[B] 公司規模、[C] 總部位置、[D] 提供的抗體發現服務類型、[E] 支援的抗體發現類型、[F] 抗體發現方法的類型、[G] 使用的動物模型以及 [H] 應用領域。
競爭分析：對抗體藥物合約製造商進行全面的競爭分析，考慮因素包括 A] 開發商實力、[B] 產品組合實力和 [C] 產品組合多樣性。
技術競爭分析：對抗體發現技術/平台進行全面的競爭分析，考察因素包括 A] 開發商實力、[B] 產品組合實力和 [C] 產品組合多樣性。
公司簡介：抗體發現市場主要開發商的詳細簡介，重點關注 A] 公司概況、[B] 財務資訊（如有）、[C] 抗體發現服務組合以及 [D] 近期發展和未來展望。
合作關係與合作：基於各種參數，例如 A) 合作年份、[B] 合作類型、[C] 抗體類型、[D] 地區等，對抗體發現市場中達成的各種合作關係與合作進行深入分析。
資金與投資分析：基於各種參數，例如 A) 融資年份、[B] 融資類型、[C] 地區等，對該領域報告的總體資金和投資進行深入分析。

Antibodies play a pivotal role in the identification and neutralization of foreign substances. Owing to several beneficial features, such as high specificity, and a favorable safety profile, these molecules have emerged as a promising alternative, particularly for the treatment of cancer, autoimmune diseases, and infectious diseases. It is worth highlighting that, at present, antibodies represent the largest class of biologics, with over 80 molecules approved till date and over 200 molecules in the preclinical / discovery stages.

Despite multiple approvals, various challenges in the domain remain unaddressed across several stages of design, production, and clinical application. Therefore, given the complexities of modern drug development, several companies prefer to outsource as a strategic solution to optimize their research efforts. This expected shift can be attributed to various reasons, such as reduced timelines, lessened financial risks associated with failed trials and accelerated workflows. At present, around 125 players are offering a wide array of antibody discovery services.

This field possesses significant promise for future breakthroughs, wherein advances in artificial intelligence and machine learning is expected to be crucial, facilitating the prediction of antibody-antigen interactions and enhancing the efficiency of lead identification.

Fueled by these developments, the antibody discovery market is expected to progress in the coming years, benefiting multiple stakeholders who have consistently fostered innovation in this field

Antibody discovery market: Key Insights

The report delves into the current state of the antibody discovery market and identifies potential growth opportunities within industry. Some key findings from the report include:

Presently, close to 125 players across the globe claim to offer customized services in order to support the operations related to antibody discovery; majority of these firms are based in North America.
A relatively large proportion (88%) of the service providers offer hit generation services; of these, 57% employ library-based methods in order to support the discovery of antibodies for different therapeutic purposes.
Close to 265 antibody discovery technologies are currently available in the market; these have revolutionized the field of antibody discovery by accelerating the identification and development of highly specific antibodies.
Nearly 60% of the technologies employ library-based methods for antibody discovery; of these, 45% of the technologies support the discovery of monoclonal antibodies.

Stakeholders are actively enhancing their existing capabilities and strengthening their competencies in order to gain an edge in the antibody discovery services domain.
In pursuit of gaining a competitive edge, industry stakeholders are actively innovating and developing novel antibody discovery technologies / platforms that can support the discovery of multiple type of antibodies.
60% of the partnership deals have been inked post-2021; technology / product licensing agreements have emerged as the most prominent types of partnership models
Foreseeing lucrative returns, many public and private investors have made investments worth USD 36 billion since 2020; of this, 70% of the total amount was raised by players based in North America.

Given the rising demand for targeted biologics and personalized medicine, the antibody discovery market is anticipated to grow at an annualized rate (CAGR) of 10.1% till 2035
The market opportunity for service providers using hybridoma-based methods is likely to be the highest; in terms of type of antibody, monoclonal antibodies sub-segment is anticipated to grow substantially.

In the long term, the antibody discovery platforms for monoclonal antibodies are likely to emerge as the key contributor; Asia-Pacific is anticipated to be the fastest growing region.

Antibody Discovery Services Market: Key Segments

Lead Optimization Segment Captures that Majority of the Market Share

Based on the antibody discovery step, the services segment of antibody discovery market is distributed across lead optimization, lead selection and hit generation. Currently, the lead optimization sub-segment occupies the majority (61%) of the share in the overall market. It is worth highlighting that lead optimization ensures the selection of high-quality antibody candidates in terms of affinity, stability, and specificity, thereby increasing their likelihood of clinical success.

Antibody Discovery Services Segment is leading the Antibody Discovery Market

Based on the discovery method, the services segment of antibody discovery market is segmented into hybridoma-based methods, phage display library-based methods, transgenic animal-based methods, yeast display-based methods, single cell-based methods and other methods.

Presently, the market is dominated by hybridoma-based methods (35%) since the popularity of hybridoma-based methods for the discovery of antibodies has risen, owing to its efficiency and low complexity. Moreover, hybridoma-based methods have been crucial in developing therapeutic monoclonal antibodies used in treatment of diseases, including cancer, autoimmune disorders, and infections.

Based on Nature of Antibody, Human Antibodies Sub-Segment Occupies the Highest Share

Based on the nature of antibody, the services segment of antibody discovery market is segmented into human antibodies, humanized antibodies, chimeric antibodies and murine antibodies. The human antibodies sub-segment occupies the highest share (53%) in the current global services market. Several benefits associated with human antibodies, including reduced immunogenicity and the increased serum half-life of the monoclonal antibodies in humans, contribute to the high market share.

Oncological Disorders Dominate the Current Antibody Discovery Market

The global market value for services segment of antibody discovery market, based on different therapeutic areas, is segmented into oncological disorders, immunological disorders, infectious diseases, cardiovascular disorders, neurological disorders and other disorders. Currently, the market is dominated by oncological disorders sub-segment (48%). This can be attributed to the fact that incidence of oncological disorders has been on the rise globally, necessitating the development and production of effective treatments, including antibody-based therapeutics.

By Type of Antibody, Monoclonal Antibodies are Likely to Dominate the Market During the Forecast Period

Based on the type of antibody, the global services segment of antibody discovery market is segmented into monoclonal antibodies, bispecific antibodies and immunoconjugates. In the current year, the market is dominated by monoclonal antibodies (60%) and the trend is unlikely to change in the future as well. This can be attributed to the fact that monoclonal antibodies offer high specificity, consistency, and reproducibility, which makes them ideal for targeted therapies. In addition, mAbs have proven to be highly effective in treating a range of diseases, including cancer, autoimmune disorders, and infectious diseases.

Similarly, based on the type of antibody, the global technologies / platforms market is segmented into monoclonal antibodies, bispecific antibodies, antibody drug conjugates and other antibodies.

The Technologies / Platforms Market is the Fastest Growing Segment of the During the Forecast Period

In terms of end-user, the global technologies / platforms market segment of antibody discovery market is segmented across different end-users, namely in-house players and contract research organizations. In-house players' sub-segment (98%) occupies the highest market share. This can be attributed to the fact that in-house players mostly have dedicated teams, access to extensive in-house resources, and control over intellectual property, which enables them to streamline the discovery process and maintain competitive advantages.

North America Accounts for the Largest Share of the Market

This segment highlights the distribution of global services market size across geographical regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Our estimates suggest that the majority share in the current year is captured by North America (50%) owing to the presence of big pharma players, well-established regulatory framework, and various technological advancements in this region. On the contrary, Asia-Pacific is poised for the healthy growth rate (with a CAGR of 13.3%) during the forecast period.

Likewise, technologies / platforms market is segmented across various geographies, including North America, Europe and Asia-Pacific. Our estimates suggest that, North America is likely to capture the majority of the overall market share driven by maximum number of technology licensing / integration deals inked by technology / platform providers headquartered in this region.

Further, the market in Asia-Pacific is anticipated to increase at a faster pace (CAGR of 9.30%) in the foreseen future.

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the market. In addition, the research report features detailed transcripts of interviews held with the industry stakeholders (arranged in decreasing order of seniority level):

Chief Executive Officer and Chief Scientific Officer, Small Company, US
Chief Executive Officer and General Manager, Small Company, Germany
Chief Executive Officer, Small Company, US
Former Chief Executive Officer, Large Company, US
Chief Business Officer, Mid-sized Company, US
Chief Business Officer, Mid-sized Company, US
Former Chief Business Officer, Small Company, US
Former Chief Scientific Officer, Large Company, US
President and Chief Operating Officer, Small Company, US
Founder and Chief Technology Officer, Small Company, US
Founder and President, Small Company, US
Vice President of Commercial Services, Mid-sized Company, US
Senior Vice President, Small Company, US
Co-founder and Director of Emerging Science and Technology, Large Company, Canada
Co-founder and Director, Small Company, India
Former Site Director, Large Company, US
Business Development Manager, Small Company, US

Example Players in the Antibody Discovery Services Market

Ablexis
Abwiz Bio
Abzena
Aragen Life Sciences
BIOTEM
ChemPartner
Creative Biolabs
DetaiBio
FairJourney Biologics
Fusion Antibodies
Genmab
Harbour BioMed
Immunome
ImmunoPrecise Antibodies
Integral Molecular
Isogenica
ProteoGenix
Syd Labs
Viva Biotech
WuXi Biologics

Antibody Discovery Services Market: Research Coverage

Antibody Discovery Services Market Sizing and Opportunity Analysis: The report features a thorough analysis of the global antibody discovery market, in terms of the key market segments, namely [A] antibody discovery step [B] type of antibody discovery method, [C] and nature of antibody [D] therapeutic area [E] type of antibody and [F] geographical regions.
Antibody Discovery Technologies / Platforms Market: The report features a thorough analysis of the global antibody discovery market, in terms of the key market segments, namely [A] type of antibody [B] type of end-user, [C] and geographical regions.
Market Landscape: An in-depth assessment of the companies involved in antibody discovery market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of antibody discovery service offered, [E] type of antibody discovery supported, [F] type of antibody discovery method, [G] animal model used, [H] application area.
Company Competitiveness Analysis: A comprehensive competitive analysis of antibody contract manufacturers, examining factors, such as [A] developer strength and [B] portfolio strength and [C] portfolio diversity.
Technology Competitiveness Analysis: A comprehensive competitive analysis of antibody discovery technologies / platforms, examining factors, such as [A] developer strength and [B] portfolio strength and [C] portfolio diversity.
Company Profiles: Detailed profiles of key developers engaged in the antibody discovery market, focused on [A] overview of the company, [B] financial information (if available), [C] antibody discovery service portfolio, and [D] recent developments and an informed future outlook.
Partnerships and Collaborations: An insightful analysis of the various partnerships and collaborations signed in the antibody discovery market, based on various parameters, such as [A] year of partnership [B] type of partnership [C] type of antibody and [D] geography.
Funding and Investment Analysis: An insightful analysis of the overall funding and investments reported in this domain, based on various parameters, such as [A] year of funding [B] type of funding and [C] geography.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

SECTION I: REPORT OVERVIEW

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics
4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Structure of Antibodies
6.3. History of Antibody Discovery
6.4. Antibody Isotypes
6.5. Mechanism of Action of Antibodies
6.6. Classification of Antibodies
- 6.6.1. Monoclonal Antibodies
- 6.6.2. Polyclonal Antibodies
- 6.6.3. Bispecific Antibodies
6.7. Applications of Antibodies
6.8. Concluding Remarks

7. ANTIBODY DISCOVERY: PROCESSES AND METHODS

7.1. Chapter Overview
7.2. Antibody Discovery Process
- 7.2.1. Target Selection and Validation
- 7.2.2. Hit Generation
- 7.2.3. Lead Selection
- 7.2.4. Lead Optimization
  - 7.2.4.1. Humanization
  - 7.2.4.2. Affinity Maturation
  - 7.2.4.3. Fc Engineering
- 7.2.5. Lead Characterization
- 7.2.6. Candidate Selection
7.3. Antibody Discovery Methods
- 7.3.1. Hybridoma Method
- 7.3.2. In Vitro Display Method
  - 7.3.2.1. Phage Display Method
  - 7.3.2.2. Yeast Display Method
  - 7.3.2.3. Ribosomal Display Method
- 7.3.3. Transgenic Animal-based Method
- 7.3.4. Single B Cell Based Method
7.4. Advantages and Disadvantages of Existing Antibody Discovery Methods
7.5. Evolution of Monoclonal Antibodies
- 7.5.1. Fully Human Monoclonal Antibodies
7.6. Concluding Remarks

SECTION III: COMPETITIVE LANDSCAPE

8. MARKET LANDSCAPE: ANTIBODY DISCOVERY SERVICE PROVIDERS

8.1. Chapter Overview
8.2. Antibody Discovery Service Providers: Market Landscape
- 8.2.1. Analysis by Year of Establishment
- 8.2.2. Analysis by Company Size
- 8.2.3. Analysis by Location of Headquarters
- 8.2.4. Analysis by Type of Antibody Discovery Service Offered
- 8.2.5. Analysis by Type of Antibody Discovery Supported
- 8.2.6. Analysis by Type of Antibody Discovery Method
- 8.2.7. Analysis by Animal Model Used
- 8.2.8. Analysis by Type of Antibody Discovery Method and Type of Antibody Discovery Supported
- 8.2.9. Analysis by Type of Antibody Discovery Service Offered and Location of Headquarters
- 8.2.10. Analysis by Application Area

9. MARKET LANDSCAPE: ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS

9.1. Chapter Overview
9.2. Antibody Discovery Technologies / Platforms: Market Landscape
- 9.2.1. Analysis by Type of Antibody Discovery Method Used
- 9.2.2. Analysis by Type of Antibody Discovery Supported
- 9.2.3. Analysis by Animal Model Used
- 9.2.4. Analysis by Type of Antibody Discovery Method Used and Type of Antibody Discovery Supported
- 9.2.5. Analysis by Type of Antibody Discovery Method and Location of Headquarters of Technology / Platform Providers
9.3. Antibody Discovery Technology / Platform Providers Landscape
- 9.3.1. Analysis by Year of Establishment
- 9.3.2. Analysis by Company Size
- 9.3.3. Analysis by Location of Headquarters
- 9.3.4. Most Active Players: Analysis by Number of Technologies

10. COMPANY COMPETITIVENESS ANALYSIS

10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Overview of Peer Groups
10.5. Company Competitiveness Analysis
- 10.5.1. Antibody Discovery Service Providers Headquartered in North America
- 10.5.2. Antibody Discovery Service Providers Headquartered in Europe
- 10.5.3. Antibody Discovery Service Providers Headquartered in Asia-Pacific

11. TECHNOLOGY COMPETITIVENESS ANALYSIS

11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Overview of Peer Groups
11.5. Technology Competitiveness Analysis
- 11.5.1. Antibody Discovery Technologies / Platforms Provided by Players Headquartered in North America
- 11.5.2. Antibody Discovery Technologies / Platforms Provided by Players Headquartered in Europe
- 11.5.3. Antibody Discovery Technologies / Platforms Provided by Players Headquartered in Asia-Pacific

SECTION IV: COMPANY PROFILES

12. ANTIBODY DISCOVERY SERVICE PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA

12.1. Chapter Overview
12.2. Abwiz Bio
- 12.2.1. Company Overview
- 12.2.2. Antibody Discovery Service Portfolio
- 12.2.3. Recent Developments and Future Outlook
12.3. Abzena
- 12.3.1. Company Overview
- 12.3.2. Antibody Discovery Service Portfolio
- 12.3.3. Recent Developments and Future Outlook
12.4. Creative Biolabs
- 12.4.1. Company Overview
- 12.4.2. Antibody Discovery Service Portfolio
- 12.4.3. Recent Developments and Future Outlook
12.5. DetaiBio
- 12.5.1. Company Overview
- 12.5.2. Antibody Discovery Service Portfolio
- 12.5.3. Recent Developments and Future Outlook
12.6. ImmunoPrecise Antibodies
- 12.6.1. Company Overview
- 12.6.2. Financial Information
- 12.6.3. Antibody Discovery Service Portfolio
- 12.6.4. Recent Developments and Future Outlook
12.7. Integral Molecular
- 12.7.1. Company Overview
- 12.7.2. Antibody Discovery Service Portfolio
- 12.7.3. Recent Developments and Future Outlook
12.8. Syd Labs
- 12.8.1. Company Overview
- 12.8.2. Antibody Discovery Service Portfolio
- 12.8.3. Recent Developments and Future outlook

13. ANTIBODY DISCOVERY SERVICE PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN EUROPE

13.1. Chapter Overview
13.2. BIOTEM
- 13.2.1. Company Overview
- 13.2.2. Antibody Discovery Service Portfolio
- 13.2.3. Recent Developments and Future Outlook
13.3. FairJourney Biologics
- 13.3.1. Company Overview
- 13.3.2. Antibody Discovery Service Portfolio
- 13.3.3. Recent Developments and Future Outlook
13.4. Fusion Antibodies
- 13.4.1. Company Overview
- 13.4.2. Financial Information
- 13.4.3. Antibody Discovery Service Portfolio
- 13.4.4. Recent Developments and Future Outlook
13.5. Proteogenix
- 13.5.1. Company Overview
- 13.5.2. Antibody Discovery Service Portfolio
- 13.5.3. Recent Developments and Future Outlook

14. ANTIBODY DISCOVERY SERVICE PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN ASIA-PACIFIC

14.1. Chapter Overview
14.2. Aragen Life Sciences
- 14.2.1. Company Overview
- 14.2.2. Antibody Discovery Service Portfolio
- 14.2.3. Recent Developments and Future Outlook
14.3. ChemPartner
- 14.3.1. Company Overview
- 14.3.2. Antibody Discovery Service Portfolio
- 14.3.3. Recent Developments and Future Outlook
14.4. Viva Biotech
- 14.4.1. Company Overview
- 14.4.2. Financial Information
- 14.4.3. Antibody Discovery Service Portfolio
- 14.4.4. Recent Developments and Future Outlook
14.5. WuXi Biologics
- 14.5.1. Company Overview
- 14.5.2. Financial Information
- 14.5.3. Antibody Discovery Service Portfolio
- 14.5.4. Recent Developments and Future Outlook

15. ANTIBODY DISCOVERY TECHNOLOGY / PLATFORM PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA

15.1. Chapter Overview
15.2. Ablexis
- 15.2.1. Company Overview
- 15.2.2. Antibody Discovery Technology / Platform Portfolio
- 15.2.3. Recent Developments and Future Outlook
15.3. Harbour BioMed
- 15.3.1. Company Overview
- 15.3.2. Antibody Discovery Technology / Platform Portfolio
- 15.3.3. Financial Information
- 15.3.4. Recent Developments and Future Outlook
15.4. Immunome
- 15.4.1. Company Overview
- 15.4.2. Antibody Discovery Technology / Platform Portfolio
- 15.4.3. Recent Developments and Future Outlook

16. ANTIBODY DISCOVERY TECHNOLOGY / PLATFORM PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN EUROPE

16.1. Chapter Overview
16.2. Genmab
- 16.2.1. Company Overview
- 16.2.2. Antibody Discovery Technology / Platform Portfolio
- 16.2.3. Financial Information
- 16.2.4. Recent Developments and Future Outlook
16.3. Isogenica
- 16.3.1. Company Overview
- 16.3.2. Antibody Discovery Technology / Platform Portfolio
- 16.3.3. Recent Developments and Future Outlook

SECTION V: MARKET TRENDS

17. PARTNERSHIPS AND COLLABORATIONS

17.1. Chapter Overview
17.2. Partnership Models
17.3. Antibody Discovery Services and Platforms: Partnerships and Collaborations
- 17.3.1. Analysis by Year of Partnership
- 17.3.2. Analysis by Type of Partnership
- 17.3.3. Analysis by Year and Type of Partnership
- 17.3.4. Analysis by Type of Antibody
- 17.3.5. Key Technologies: Analysis by Number of Partnerships
- 17.3.6. Most Active Players: Analysis by Number of Partnerships
- 17.3.7. Analysis by Geography
  - 17.3.7.1. Local and International Agreements
  - 17.3.7.2. Intracontinental and Intercontinental Agreements

18. FUNDING AND INVESTMENT ANALYSIS

18.1. Chapter Overview
18.2. Types of Funding
18.3. Antibody Discovery Service and Platform Providers: Funding and Investment Analysis
- 18.3.1. Analysis by Year of Funding
  - 18.3.1.1. Cumulative Year-wise Trend of Funding Instances
  - 18.3.1.2. Cumulative Year-wise Trend of Amount Invested
- 18.3.2. Analysis by Type of Funding
  - 18.3.2.1. Analysis by Funding Instances
  - 18.3.2.2. Analysis by Amount Invested
- 18.3.3. Analysis by Year and Type of Funding
- 18.3.4. Analysis by Number of Funding Instances and Type of Players
- 18.3.5. Analysis by Type of Player Amount Invested
- 18.3.6. Analysis by Geography
- 18.3.7. Most Active Players: Analysis by Number of Funding Instances
- 18.3.8. Most Active Players: Analysis by Amount Invested
- 18.3.9. Leading Investors: Analysis by Number of Funding Instances
18.4. Summary of Investments

SECTION VI: MARKET OPPORTUNITY ANALYSIS

19. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

19.1. Chapter Overview
19.2. Market Drivers
19.3. Market Restraints
19.4. Market Opportunities
19.5. Market Challenges
19.6. Conclusion

20. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET

20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Antibody Discovery Services Market, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 20.3.1. Scenario Analysis
  - 20.3.1.1. Conservative Scenario
  - 20.3.1.2. Optimistic Scenario
20.4. Key Market Segmentations

21. ANTIBODY DISCOVERY SERVICES MARKET, BY ANTIBODY DISCOVERY STEP

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Antibody Discovery Services Market: Distribution by Antibody Discovery Step
- 21.3.1. Antibody Discovery Services Market for Hit Generation, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 21.3.2. Antibody Discovery Services Market for Lead Selection, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 21.3.3. Antibody Discovery Services Market for Lead Optimization, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
21.4. Data Triangulation and Validation

22. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Antibody Discovery Services Market: Distribution by Type of Antibody Discovery Method
- 22.3.1. Antibody Discovery Services Market for Hybridoma-based Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 22.3.2. Antibody Discovery Services Market for Phage Display Library-based Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 22.3.3. Antibody Discovery Services Market for Transgenic Animal-based Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 22.3.4. Antibody Discovery Services Market for Yeast Display-based Methods, Historical Trends (since 2020) and Forecasted Estimate, (till 2035)
- 22.3.5. Antibody Discovery Services Market for Single Cell-based Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 22.3.6. Antibody Discovery Services Market for Other Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation

23. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Antibody Discovery Services Market: Distribution by Nature of Antibody
- 23.3.1. Antibody Discovery Services Market for Human Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 23.3.2. Antibody Discovery Services Market for Humanized Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 23.3.3. Antibody Discovery Services Market for Chimeric Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 23.3.4. Antibody Discovery Services Market for Murine Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
23.4. Data Triangulation and Validation

24. ANTIBODY DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Antibody Discovery Services Market: Distribution by Therapeutic Area
- 24.3.1. Antibody Discovery Services Market for Oncological Disorders, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 24.3.2. Antibody Discovery Services Market for Immunological Disorders, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 24.3.3. Antibody Discovery Services Market for Infectious Diseases, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 24.3.4. Antibody Discovery Services Market for Cardiovascular Disorders, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 24.3.5. Antibody Discovery Services Market for Neurological Disorders, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 24.3.6. Antibody Discovery Services Market for Other Disorders, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
24.4. Data Triangulation and Validation

25. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Antibody Discovery Services Market: Distribution by Type of Antibody
- 25.3.1. Antibody Discovery Services Market for Monoclonal Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 25.3.2. Antibody Discovery Services Market for Bispecific Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 25.3.3. Antibody Discovery Services Market for Immunoconjugates, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation

26. ANTIBODY DISCOVERY SERVICES MARKET, BY GEOGRAPHICAL REGIONS

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Antibody Discovery Services Market: Distribution by Geographical Regions
- 26.3.1. Antibody Discovery Services Market in North America, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.1.1. Antibody Discovery Services Market in the US, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.1.2. Antibody Discovery Services Market in Canada, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 26.3.2. Antibody Discovery Services Market in Europe, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.1. Antibody Discovery Services Market in Germany, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.2. Antibody Discovery Services Market in the UK, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.3. Antibody Discovery Services Market in France, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.4. Antibody Discovery Services Market in Italy, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.5. Antibody Discovery Services Market in Spain, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.2.6. Antibody Discovery Services Market in Rest of Europe, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 26.3.3. Antibody Discovery Services Market in Asia-Pacific, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.3.1. Antibody Discovery Services Market in China, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.3.2. Antibody Discovery Services Market in Japan, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.3.3. Antibody Discovery Services Market in India, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.3.4. Antibody Discovery Services Market in South Korea, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.3.5. Antibody Discovery Services Market in Australia, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 26.3.4. Antibody Discovery Services Market in Middle East and North Africa, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.4.1. Antibody Discovery Services Market in Egypt, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.4.2. Antibody Discovery Services Market in Israel, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.4.3. Antibody Discovery Services Market in Saudi Arabia, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.4.4. Antibody Discovery Services Market in Rest of Middle East and North Africa, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
- 26.3.5. Antibody Discovery Services Market in Latin America, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.5.1. Antibody Discovery Services Market in Brazil, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.5.2. Antibody Discovery Services Market in Argentina, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.5.3. Antibody Discovery Services Market in Mexico, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
  - 26.3.5.4. Antibody Discovery Services Market in Rest of Latin America, Historical Trends (since 2020) and Forecasted Estimates (till 2035)
26.4. Antibody Discovery Services Market, by Geographical Regions: Market Dynamics Assessment
- 26.4.1. Penetration Growth (P-G) Matrix
- 26.4.2. Market Movement Analysis
26.5. Data Triangulation and Validation

27. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS MARKET

27.1. Chapter Overview
27.2. Assumptions and Methodology
27.3. Antibody Discovery Technologies / Platforms Market: Forecasted Estimates, till 2035
- 27.3.1. Scenario Analysis
  - 27.3.1.1. Conservative Scenario
  - 27.3.1.2. Optimistic Scenario
27.4. Key Market Segmentations

28. ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS MARKET, BY TYPE OF ANTIBODY

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Antibody Discovery Technologies / Platforms Market: Distribution by Type of Antibody
- 28.3.1. Antibody Discovery Technologies / Platforms Market for Monoclonal Antibodies, Forecasted Estimates (till 2035)
- 28.3.2. Antibody Discovery Technologies / Platforms Market for Bispecific Antibodies, Forecasted Estimates (till 2035)
- 28.3.3. Antibody Discovery Technologies / Platforms Market for Antibody Drug Conjugates, Forecasted Estimates (till 2035)
- 28.3.4. Antibody Discovery Technologies / Platforms Market for Other Antibodies, Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation

29. ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS MARKET, BY TYPE OF END-USER

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Antibody Discovery Technologies / Platforms Market: Distribution by Type of End-User
- 29.3.1. Antibody Discovery Technologies / Platforms Market for In-house, Forecasted Estimates (till 2035)
- 29.3.2. Antibody Discovery Technologies / Platforms Market for Contract Research Organizations, Forecasted Estimates (till 2035)
29.4. Data Triangulation and Validation

30. ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS MARKET, BY GEOGRAPHICAL REGIONS

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Antibody Discovery Technologies / Platforms: Distribution by Geographical Regions
- 30.3.1. Antibody Discovery Technologies / Platforms Market in North America, Forecasted Estimates (till 2035)
  - 30.3.1.1. Antibody Discovery Technologies / Platforms Market in the US, Forecasted Estimates (till 2035)
  - 30.3.1.2. Antibody Discovery Technologies / Platforms Market in Canada, Forecasted Estimates (till 2035)
- 30.3.2. Antibody Discovery Technologies / Platforms Market in Europe, Forecasted Estimates (till 2035)
  - 30.3.2.1. Antibody Discovery Technologies / Platforms Market in Switzerland, Forecasted Estimates (till 2035)
  - 30.3.2.2. Antibody Discovery Technologies / Platforms Market in Germany, Forecasted Estimates (till 2035)
  - 30.3.2.3. Antibody Discovery Technologies / Platforms Market in the UK, Forecasted Estimates (till 2035)
  - 30.3.2.4. Antibody Discovery Technologies / Platforms Market in France, Forecasted Estimates (till 2035)
  - 30.3.2.5. Antibody Discovery Technologies / Platforms Market in Rest of Europe, Forecasted Estimates (till 2035)
- 30.3.3. Antibody Discovery Technologies / Platforms Market in Asia-Pacific, Forecasted Estimates (till 2035)
  - 30.3.3.1. Antibody Discovery Technologies / Platforms Market in China, Forecasted Estimates (till 2035)
  - 30.3.3.2. Antibody Discovery Technologies / Platforms Market in Singapore, Forecasted Estimates (till 2035)
  - 30.3.3.3. Antibody Discovery Technologies / Platforms Market in Japan, Forecasted Estimates (till 2035)
  - 30.3.3.4. Antibody Discovery Technologies / Platforms Market in South Korea, Forecasted Estimates (till 2035)
30.4. Market Dynamics Assessment
- 30.4.1. Penetration Growth (P-G) Matrix
30.5. Data Triangulation and Validation

31. LICENSING DEAL STRUCTURE

31.1. Chapter Overview
31.2. Key Parameters
31.3. Assumptions and Methodology
- 31.3.1. Overall Cash Flow for Licensee Companies
  - 31.3.1.1. Total Expenses Incurred by a Licensee
  - 31.3.1.2. Revenues Generated by a Licensee
- 31.3.2. Overall Cash Flow for Licensor
  - 31.3.2.1. Total Expenses Incurred by the Licensor
  - 31.3.2.2. Revenues by the Licensor
31.4. Key Analytical Outputs
- 31.4.1. Scenario 1: Variation of Upfront Payments and Milestone Payments
- 31.4.2. Scenario 2: Variation of Upfront Payments and Sales based Royalties
- 31.4.3. Scenario 1: Variation of Milestone Payments and Sales based Royalties

32. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES

32.1. Chapter Overview
32.2. Humira (Adalimumab)
- 32.2.1. Drug Overview
- 32.2.2. Discovery Process and Method
- 32.2.3. Historical Sales
32.3. Keytruda (Pembrolizumab)
- 32.3.1. Drug Overview
- 32.3.2. Discovery Process and Method
- 32.3.3. Historical Sales
32.4. Stelara (Ustekinumab)
- 32.4.1. Drug Overview
- 32.4.2. Discovery Process and Method
- 32.4.3. Historical Sales
32.5. Opdivo (Nivolumab)
- 32.5.1. Drug Overview
- 32.5.2. Discovery Process and Method
- 32.5.3. Historical Sales
32.6. Darzalex (Daratumumab)
- 32.6.1. Drug Overview
- 32.6.2. Discovery Process and Method
- 32.6.3. Historical Sales

33. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY

33.1. Chapter Overview
33.2. Upcoming Trends in Drug Discovery
33.3. Anticipated Shift from Monoclonal Antibodies to Other Novel Antibody Formats
- 33.3.1. Technological Advancements to Overhaul Conventional Antibody Discovery Processes
- 33.3.2. Transition to CADD-based Approaches to Help Achieve Better Operational Efficiencies
- 33.3.3. Rising Demand for Antibody-based Treatment Options for Non-Oncological Indications
33.4. Future Growth Opportunities in Emerging Economies
33.5. Concluding Remarks

SECTION VII: OTHER EXCLUSIVE INSIGHTS

34. CONCLUDING INSIGHTS

35. EXECUTIVE INSIGHTS

SECTION VIII: APPENDICES

36. APPENDIX I: TABULATED DATA

37. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

簡介目錄圖表

List of Tables

Table 6.1 Features of Different Isotypes of Antibodies
Table 6.2 Mechanism of Action of Therapeutic Antibodies Against Different Target Classes
Table 6.3 Differences Between Polyclonal and Monoclonal Antibodies
Table 7.1 Antibody Discovery Methods: Advantages and Disadvantages
Table 7.2 List of Approved Monoclonal Antibodies
Table 7.3 Approval Timeline: Fully Human Monoclonal Antibodies
Table 8.1 Antibody Discovery Service Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 8.2 Antibody Discovery Service Providers: Information on Type of Antibody Discovery Service Offered
Table 8.3 Antibody Discovery Service Providers: Information on Type of Antibody Discovery Supported
Table 8.4 Antibody Discovery Service Providers: Information on Type of Antibody Discovery Method Used
Table 8.5 Antibody Discovery Service Providers: Information on Animal Model Used
Table 8.6 Antibody Discovery Service Providers: Information on Application Area
Table 9.1 List of Antibody Discovery Technologies / Platforms
Table 9.2 Antibody Discovery Technologies / Platforms: Information on Antibody Discovery Method Used
Table 9.3 Antibody Discovery Technologies / Platforms: Information on Type of Antibody Discovery Supported
Table 9.4 Antibody Discovery Technologies / Platforms: Information on Animal Model Used
Table 9.5 Antibody Discovery Technology / Platform Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 10.1 Company Competitiveness Scores Allotted to Service Providers based in North America (Peer Group I)
Table 10.2 Company Competitiveness Scores Allotted to Service Providers based in Europe (Peer Group II)
Table 10.3 Company Competitiveness Scores Allotted to Service Providers based in Asia-Pacific (Peer Group III)
Table 11.1 Technology Competitiveness Analysis: Antibody Discovery Technologies / Platforms Provided by Players Headquartered in North America (Peer Group I)
Table 11.2 Company Competitiveness Scores Allotted to Service Providers based in Europe (Peer Group II)
Table 11.3 Company Competitiveness Scores Allotted to Service Providers based in Asia-Pacific (Peer Group III)
Table 12.1 Antibody Discovery Service Providers in North America: List of Companies Profiled
Table 12.2 Abwiz Bio: Company Snapshot
Table 12.3 Abwiz Bio: Antibody Discovery Service Portfolio
Table 12.4 Abzena: Company Snapshot
Table 12.5 Abzena: Antibody Discovery Service Portfolio
Table 12.6 Abzena: Recent Developments and Future Outlook
Table 12.7 Creative Biolabs: Company Snapshot
Table 12.8 Creative Biolabs: Antibody Discovery Service Portfolio
Table 12.9 Creative Biolabs: Recent Developments and Future Outlook
Table 12.10 DetaiBio: Company Snapshot
Table 12.11 DetaiBio: Antibody Discovery Service Portfolio
Table 12.12 DetaiBio: Recent Developments and Future Outlook
Table 12.13 ImmunoPrecise Antibodies: Company Snapshot
Table 12.14 ImmunoPrecise Antibodies: Antibody Discovery Service Portfolio
Table 12.15 ImmunoPrecise Antibodies: Recent Developments and Future Outlook
Table 12.16 Integral Molecular: Company Snapshot
Table 12.17 Integral Molecular: Antibody Discovery Service Portfolio
Table 12.18 Integral Molecular: Recent Developments and Future Outlook
Table 12.19 Syd Labs: Company Snapshot
Table 12.20 Syd Labs: Antibody Discovery Service Portfolio
Table 13.1 Antibody Discovery Service Providers in Europe: List of Companies Profiled
Table 13.2 BIOTEM: Company Snapshot
Table 13.3 BIOTEM: Antibody Discovery Service Portfolio
Table 13.4 BIOTEM: Recent Developments and Future Outlook
Table 13.5 FairJourney Biologics: Company Snapshot
Table 13.6 FairJourney Biologics: Antibody Discovery Service Portfolio
Table 13.7 FairJourney Biologics: Recent Developments and Future Outlook
Table 13.8 Fusion Antibodies: Company Snapshot
Table 13.9 Fusion Antibodies: Antibody Discovery Service Portfolio
Table 13.10 Fusion Antibodies: Recent Developments and Future Outlook
Table 13.11 ProteoGenix: Company Snapshot
Table 13.12 ProteoGenix: Antibody Discovery Service Portfolio
Table 13.13 ProteoGenix: Recent Developments and Future Outlook
Table 14.1 Antibody Discovery Service Providers in Asia-Pacific: List of Companies Profiled
Table 14.2 Aragen Life Sciences: Company Snapshot
Table 14.3 Aragen Life Sciences: Antibody Discovery Service Portfolio
Table 14.4 Aragen Life Sciences: Recent Developments and Future Outlook
Table 14.5 ChemPartner: Company Snapshot
Table 14.6 ChemPartner: Antibody Discovery Service Portfolio
Table 14.7 ChemPartner: Recent Developments and Future Outlook
Table 14.8 Viva Biotech: Company Snapshot
Table 14.9 Viva Biotech: Antibody Discovery Service Portfolio
Table 14.10 Viva Biotech: Recent Developments and Future Outlook
Table 14.11 WuXi Biologics: Company Snapshot
Table 14.12 WuXi Biologics: Antibody Discovery Service Portfolio
Table 14.13 WuXi Biologics: Recent Developments and Future Outlook
Table 15.1 Antibody Discovery Technology / Platform Providers in North America: List of Companies Profiled
Table 15.2 Ablexis: Company Snapshot
Table 15.3 Ablexis: Antibody Discovery Platform Portfolio
Table 15.4 Ablexis: Recent Developments and Future Outlook
Table 15.5 Harbour BioMed: Company Snapshot
Table 15.6 Harbour BioMed: Antibody Discovery Platform Portfolio
Table 15.7 Harbour BioMed: Recent Development and Future Outlook
Table 15.8 Immunome: Company Snapshot
Table 15.9 Immunome: Antibody Discovery Platform Portfolio
Table 15.10 Immunome: Recent Developments and Future Outlook
Table 16.1 Antibody Discovery Technology / Platform Providers in Europe: List of Companies Profiled
Table 16.2 Genmab: Company Snapshot
Table 16.3 Genmab: Antibody Discovery Platform Portfolio
Table 16.4 Genmab: Recent Developments and Future Outlook
Table 16.5 Isogenica: Company Snapshot
Table 16.6 Isogenica: Antibody Discovery Platform Portfolio
Table 16.7 Isogenica: Recent Developments and Future Outlook
Table 17.1 Antibody Discovery Services and Platforms Market: List of Partnerships and Collaborations, Since 2021
Table 17.2 Partnerships and Collaborations: Information on Type of Agreement
Table 18.1 Antibody Discovery Services and Platforms Market: List of Funding and Investments, Since 2021
Table 27.1 Antibody Discovery Technologies Market: Average Upfront Payment and Average Milestone Payment, Since 2021 (USD Million)
Table 27.2 Licensing Deals: Tranches of Milestone Payments
Table 31.1 Scenario 1: Multiple Cases of Varying Upfront and Milestone Payments
Table 31.2 Scenario 2: Multiple Cases of Varying Upfront Payment and Sales based Royalties
Table 31.3 Multiple Cases of Varying Milestone Payment and Sales based Royalties
Table 32.1 Top Seven Selling Therapeutic Antibodies, 2024
Table 33.1 Antibody Discovery Services and Platform Providers Headquartered in Asia-Pacific
Table 35.1 Antibody Solutions: Company Snapshot
Table 35.2 Adimab: Company Snapshot
Table 35.3 ImmunoPrecise Antibodies: Company Snapshot
Table 35.4 Abveris Antibody: Company Snapshot
Table 35.5 Nidus BioSciences: Company Snapshot
Table 35.6 AvantGen: Company Snapshot
Table 35.7 Single Cell Technology: Company Snapshot
Table 35.8 Distributed Bio (acquired by Charles River): Company Snapshot
Table 35.9 AbCellera: Company Snapshot
Table 35.10 AbGenics Life Sciences: Company Snapshot
Table 35.11 CDI Laboratories: Company Snapshot
Table 35.12 AP Biosciences: Company Snapshot
Table 35.13 YUMAB: Company Snapshot
Table 35.14 Antibody Solutions: Company Snapshot
Table 35.15 Ligand Pharmaceuticals: Company Snapshot
Table 35.16 LakePharma (acquired by Curia): Company Snapshot
Table 36.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Table 36.2 Antibody Discovery Service Providers: Distribution by Company Size
Table 36.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters (Region)
Table 36.4 Antibody Discovery Service Providers: Distribution by Location of Headquarters (Country)
Table 36.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Service Offered
Table 36.6 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Supported
Table 36.7 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method Used
Table 36.8 Antibody Discovery Service Providers: Distribution by Animal Model Used
Table 36.9 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method Used and Type of Antibody Discovery Supported
Table 36.10 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Service Offered and Location of Headquarters
Table 36.11 Antibody Discovery Service Providers: Distribution by Application Area
Table 36.12 Antibody Discovery Technologies / Platforms: Distribution by Type of Antibody Discovery Method Used
Table 36.13 Antibody Discovery Technologies / Platforms: Distribution by Type of Antibody Discovery Supported
Table 36.14 Antibody Discovery Technologies / Platforms: Distribution by Animal Model Used
Table 36.15 Antibody Discovery Technologies / Platforms: Distribution by Antibody Discovery Method Used and Type of Antibody Discovery Supported
Table 36.16 Antibody Discovery Technologies / Platforms: Distribution by Type of Antibody Discovery Method and Location of Headquarters of the Technology / Platform Provider
Table 36.17 Antibody Discovery Technology / Platform Providers: Distribution by Year of Establishment
Table 36.18 Antibody Discovery Technology / Platform Providers: Distribution by Company Size
Table 36.19 Antibody Discovery Technology / Platform Providers: Distribution by Location of Headquarters (Region)
Table 36.20 Antibody Discovery Technology / Platform Providers: Distribution by Location of Headquarters (Country)
Table 36.21 Most Active Players: Distribution by Number of Technologies / Platforms
Table 36.22 ImmunoPrecise Antibodies: Consolidated Financial Details (CAD Million), Since 2022
Table 36.23 Fusion Antibodies: Business Segment-wise Revenues and Consolidated Financial Details (GBP Million), Since 2021
Table 36.24 Viva Biotech: Consolidated Financial Details (RMB Billion), Since 2021
Table 36.25 WuXi Biologics: Business Segment-wise Revenues and Consolidated Financial Details (RMB Billion), Since 2021
Table 36.26 Genmab: Consolidated Financial Details (DKK Billion), Since 2021
Table 36.27 Harbour BioMed: Consolidated Financial Details (USD Million), FY 2021-H1 FY 2024
Table 36.28 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Table 36.29 Partnerships and Collaborations: Distribution by Type of Partnership
Table 36.30 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2021
Table 36.31 Partnerships and Collaborations: Distribution by Type of Antibody
Table 36.32 Key Technologies: Distribution by Number of Partnerships
Table 36.33 Most Active Players: Distribution by Number of Partnerships
Table 36.34 Partnerships and Collaborations: Distribution by Country
Table 36.35 Partnerships and Collaborations: Distribution by Region
Table 36.36 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2020
Table 36.37 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Since 2020 (USD Million)
Table 36.38 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Table 36.39 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 36.40 Funding and Investment Analysis: Distribution by Year and Type of Funding, Since 2020
Table 36.41 Funding and Investment Analysis: Distribution by Number of Funding Instances and Type of Player
Table 36.42 Funding and Investment Analysis: Distribution by Type of Player and Amount Invested
Table 36.43 Funding and Investment Analysis: Distribution by Geography
Table 36.44 Most Active Players: Distribution by Number of Funding Instances
Table 36.45 Most Active Players: Distribution by Amount Invested (USD Million)
Table 36.46 Leading Investors: Distribution by Number of Funding Instances
Table 36.47 Global Antibody Discovery Services Market, Historical Trends (since 2020) and Forecasted Estimates (till 2035): Base Scenario (USD Million)
Table 36.48 Global Antibody Discovery Services Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Table 36.49 Global Antibody Discovery Services Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Table 36.50 Global Antibody Discovery Services Market: Distribution by Type of Antibody Discovery Step
Table 36.51 Antibody Discovery Services Market for Hit Generation: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.52 Antibody Discovery Services Market for Lead Selection: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.53 Antibody Discovery Services Market for Lead Optimization; Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.54 Global Antibody Discovery Services Market: Distribution by Type of Antibody Discovery Method
Table 36.55 Antibody Discovery Services Market for Hybridoma-based Methods: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.56 Antibody Discovery Services Market for Phage Display-based Methods: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.57 Antibody Discovery Services Market for Transgenic Animal-based Methods: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.58 Antibody Discovery Services Market for Yeast Display-based Methods; Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.59 Antibody Discovery Services Market for Single Cell-based Methods: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.60 Antibody Discovery Services Market for Other Methods: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.61 Global Antibody Discovery Services Market: Distribution by Nature of Antibody
Table 36.62 Antibody Discovery Services Market for Human Antibodies: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.63 Antibody Discovery Services Market for Humanized Antibodies: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.64 Antibody Discovery Services Market for Chimeric Antibodies: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.65 Antibody Discovery Services Market for Murine Antibodies: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.66 Global Antibody Discovery Services Market: Distribution by Therapeutic Area
Table 36.67 Antibody Discovery Services Market for Oncological Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.68 Antibody Discovery Services Market for Immunological Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.69 Antibody Discovery Services Market for Infectious Diseases: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.70 Antibody Discovery Services Market for Cardiovascular Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.71 Antibody Discovery Services Market for Neurological Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.72 Antibody Discovery Services Market for Other Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.73 Antibody Discovery Services Market: Distribution by Type of Antibody
Table 36.74 Antibody Discovery Services Market for Monoclonal Antibodies: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.75 Antibody Discovery Services Market for Bispecific Antibodies: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.76 Antibody Discovery Services Market for Immunoconjugates: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.77 Antibody Discovery Services Market: Distribution by Geographical Regions
Table 36.78 Antibody Discovery Services Market in North America: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.79 Antibody Discovery Services Market in the US: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.80 Antibody Discovery Services Market in Canada: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.81 Antibody Discovery Services Market in Europe: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.82 Antibody Discovery Services Market in Germany: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.83 Antibody Discovery Services Market in the UK: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.84 Antibody Discovery Services Market in France: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.85 Antibody Discovery Services Market in Italy: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.86 Antibody Discovery Services Market in Spain: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.87 Antibody Discovery Services Market in the Rest of Europe: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.88 Antibody Discovery Services Market in Asia-Pacific: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.89 Antibody Discovery Services Market in China: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.90 Antibody Discovery Services Market in Japan: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.91 Antibody Discovery Services Market in India: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.92 Antibody Discovery Services Market in South Korea: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.93 Antibody Discovery Services Market in Australia: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.94 Antibody Discovery Services Market in Middle East and North Africa: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.95 Antibody Discovery Services Market in Egypt: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.96 Antibody Discovery Services Market in Israel: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.97 Antibody Discovery Services Market in Saudi Arabia: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.98 Antibody Discovery Services Market in the Rest of Middle East and North Africa: Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Table 36.99 Antibody Discovery Services Market in Latin America: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.100 Antibody Discovery Services Market in Brazil: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.101 Antibody Discovery Services Market in Argentina: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.102 Antibody Discovery Services Market in Mexico: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.103 Antibody Discovery Services Market in the Rest of Latin America: Historical Trends (since 2020) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.104 Global Antibody Discovery Technologies / Platforms Market, Forecasted Estimates (till 2035): Base Scenario (USD Million)
Table 36.105 Global Antibody Discovery Technologies / Platforms Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Table 36.106 Global Antibody Discovery Technologies / Platforms Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Table 36.107 Antibody Discovery Technologies / Platforms Market: Distribution by Type of Antibody
Table 36.108 Antibody Discovery Technologies / Platforms Market for Monoclonal Antibodies: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.109 Antibody Discovery Technologies / Platforms Market for Bispecific Antibodies: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.110 Antibody Discovery Technologies / Platforms Market for Antibody Drug Conjugates: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.111 Antibody Discovery Technologies / Platforms Market for Other Antibodies: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.112 Antibody Discovery Technologies / Platforms Market: Distribution by Type of End-User
Table 36.113 Antibody Discovery Technologies / Platforms Market for In-house: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.114 Antibody Discovery Technologies / Platforms Market for Contract Research Organizations: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.115 Antibody Discovery Technologies / Platforms Market: Distribution by Geographical Regions
Table 36.116 Antibody Discovery Technologies / Platforms Market in North America: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.117 Antibody Discovery Technologies / Platforms Market in the US: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.118 Antibody Discovery Technologies / Platforms Market in Canada: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.119 Antibody Discovery Technologies / Platforms Market in Europe: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.120 Antibody Discovery Technologies / Platforms Market in Switzerland: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.121 Antibody Discovery Technologies / Platforms Market in Germany: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.122 Antibody Discovery Technologies / Platforms Market in the UK: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.123 Antibody Discovery Technologies / Platforms Market in France: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.124 Antibody Discovery Technologies / Platforms Market in the Rest of Europe: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.125 Antibody Discovery Technologies / Platforms Market in Asia-Pacific: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.126 Antibody Discovery Technologies / Platforms Market in China: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.127 Antibody Discovery Technologies / Platforms Market in Singapore: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.128 Antibody Discovery Technologies / Platforms Market in Japan: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.129 Antibody Discovery Technologies / Platforms Market in South Korea: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
Table 36.130 Total Product Sales of a Drug (USD Million)
Table 36.131 Overall Cash Flow of Licensee (USD Million)
Table 36.132 Overall Cash Flow of Licensor (USD Million)
Table 36.133 Keytruda: Annual Sales, Since 2020 (USD Billion)
Table 36.134 Dupixent: Annual Sales, Since 2020 (USD Billion)
Table 36.135 Stelara: Annual Sales, Since 2020 (USD Billion)
Table 36.136 Skyrizi: Annual Sales, Since 2020 (USD Billion)
Table 36.137 Darzalex: Annual Sales, Since 2020 (USD Billion)
Table 36.138 Opdivo: Annual Sales, Since 2020 (USD Billion)
Table 36.139 Humira: Annual Sales, Since 2020 (USD Billion)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Key Market Segmentation
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Antibody Discovery Services and Platforms Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Basic Structure of an Antibody
Figure 6.2 Historical Timeline of Antibody Development
Figure 6.3 Various Mechanisms of Action of Antibodies
Figure 7.1 Overview of the Antibody Discovery Process
Figure 7.2 Antibody Discovery Process: Hybridoma Method
Figure 7.3 Antibody Discovery Process: Phage Display Method
Figure 7.4 Antibody Discovery Process: Transgenic Animal-based Method
Figure 8.1 Antibody Discovery Service Providers: Distribution by Year of Establishment
Figure 8.2 Antibody Discovery Service Providers: Distribution by Company Size
Figure 8.3 Antibody Discovery Service Providers: Distribution by Location of Headquarters (Region)
Figure 8.4 Antibody Discovery Service Providers: Distribution by Location of Headquarters (Country)
Figure 8.5 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Service Offered
Figure 8.6 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Supported
Figure 8.7 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method
Figure 8.8 Antibody Discovery Service Providers: Distribution by Animal Model Used
Figure 8.9 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Method and Type of Antibody Discovery Supported
Figure 8.10 Antibody Discovery Service Providers: Distribution by Type of Antibody Discovery Service Offered and Location of Headquarters
Figure 8.11 Antibody Discovery Service Providers: Distribution by Application Area
Figure 9.1 Antibody Discovery Technologies / Platforms: Distribution by Type of Antibody Discovery Method Used
Figure 9.2 Antibody Discovery Technologies / Platforms: Distribution by Type of Antibody Discovery Supported
Figure 9.3 Antibody Discovery Technologies / Platforms: Distribution by Animal Model Used
Figure 9.4 Antibody Discovery Technologies / Platforms: Distribution by Antibody Discovery Method Used and Type of Antibody Discovery Supported
Figure 9.5 Antibody Discovery Technologies / Platforms: Distribution by Type of Antibody Discovery Method and Location of Headquarters of the Technology / Platform Provider
Figure 9.6 Antibody Discovery Technology / Platform Providers: Distribution by Year of Establishment
Figure 9.7 Antibody Discovery Technology / Platform Providers: Distribution by Company Size
Figure 9.8 Antibody Discovery Technology / Platform Providers: Distribution by Location of Headquarters (Region)
Figure 9.9 Antibody Discovery Technology / Platform Providers: Distribution by Location of Headquarters (Country)
Figure 9.10 Most Active Players: Distribution by Number of Technologies / Platforms
Figure 10.1 Company Competitiveness Analysis: Overview of Peer Group I
Figure 10.2 Company Competitiveness Analysis: Overview of Peer Group II
Figure 10.3 Company Competitiveness Analysis: Overview of Peer Group III
Figure 10.4 Company Competitiveness Analysis: Antibody Discovery Service Providers Headquartered in North America (Peer Group I)
Figure 10.5 Company Competitiveness Analysis: Antibody Discovery Service Providers Headquartered in Europe (Peer Group II)
Figure 10.6 Company Competitiveness Analysis: Antibody Discovery Service Providers Headquartered in Asia-Pacific (Peer Group III)
Figure 11.1 Technology Competitiveness Analysis: Overview of Peer Group I
Figure 11.2 Technology Competitiveness Analysis: Overview of Peer Group II
Figure 11.3 Technology Competitiveness Analysis: Overview of Peer Group III
Figure 11.4 Technology Competitiveness Analysis: Antibody Discovery Technologies / Platforms Provided by Players Headquartered in North America (Peer Group I)
Figure 11.5 Technology Competitiveness Analysis: Antibody Discovery Technologies / Platforms Provided by Players Headquartered in Europe (Peer Group II)
Figure 11.6 Technology Competitiveness Analysis: Antibody Discovery Technologies / Platforms Provided by Players Headquartered in Asia-Pacific (Peer Group III)
Figure 12.1 ImmunoPrecise Antibodies: Consolidated Financial Details (CAD Million), Since 2022
Figure 13.1 Fusion Antibodies: Business Segment-wise Revenues and Consolidated Financial Details (CAD Million), Since 2021
Figure 14.1 Viva Biotech: Consolidated Financial Details (RMB Billion), Since 2021
Figure 14.2 WuXi Biologics: Business Segment-wise Revenues and Consolidated Financial Details (RMB Billion), Since 2021
Figure 15.1 Harbour BioMed: Consolidated Financial Details (USD Million), FY 2021-H1 FY 2024
Figure 16.1 Genmab: Consolidated Financial Details (DKK Billion), Since 2021
Figure 17.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Figure 17.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 17.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2021
Figure 17.4 Partnerships and Collaborations: Distribution by Type of Antibody
Figure 17.5 Key Technologies: Distribution by Number of Partnerships
Figure 17.6 Most Active Players: Distribution by Number of Partnerships
Figure 17.7 Partnerships and Collaborations: Distribution by Country
Figure 17.8 Partnerships and Collaborations: Distribution by Region
Figure 18.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Since 2020
Figure 18.2 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Since 2020 (USD Million)
Figure 18.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Figure 18.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 18.5 Funding and Investment Analysis: Distribution by Year and Type of Funding, Since 2020
Figure 18.6 Funding and Investment Analysis: Distribution by Number of Funding Instances and Type of Player, Since 2020
Figure 18.7 Funding and Investment Analysis: Distribution by Type of Player and Amount Invested
Figure 18.8 Funding and Investment Analysis: Distribution by Geography
Figure 18.9 Most Active Players: Distribution by Number of Funding Instances
Figure 18.10 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 18.11 Leading Investors: Distribution by Number of Funding Instances
Figure 18.12 Funding and Investment Analysis: Summary of Investments
Figure 20.1 Global Antibody Discovery Services Market, Historical Trends (since 2020) and Forecasted Estimates (till 2035): Base Scenario (USD Million)
Figure 20.2 Global Antibody Discovery Services Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 20.3 Global Antibody Discovery Services Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 21.1 Global Antibody Discovery Services Market: Distribution by Type of Antibody Discovery Step
Figure 21.2 Antibody Discovery Services Market for Hit Generation, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.3 Antibody Discovery Services Market for Lead Selection, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.4 Antibody Discovery Services Market for Lead Optimization, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.1 Global Antibody Discovery Services Market: Distribution by Type of Antibody Discovery Method
Figure 22.2 Antibody Discovery Services Market for Hybridoma-based Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.3 Antibody Discovery Services Market for Phage Display-based Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.4 Antibody Discovery Services Market for Transgenic Animal-based Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.5 Antibody Discovery Services Market for Yeast Display-based Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.6 Antibody Discovery Services Market for Single Cell-based Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.7 Antibody Discovery Services Market for Other Methods, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.1 Global Antibody Discovery Services Market: Distribution by Nature of Antibody
Figure 23.2 Antibody Discovery Services Market for Human Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.3 Antibody Discovery Services Market for Humanized Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.4 Antibody Discovery Services Market for Chimeric Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 23.5 Antibody Discovery Services Market for Murine Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.1 Global Antibody Discovery Services Market: Distribution by Therapeutic Area
Figure 24.2 Antibody Discovery Services Market for Oncological Disorders, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.3 Antibody Discovery Services Market for Immunological Disorders, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.4 Antibody Discovery Services Market for Infectious Diseases, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.5 Antibody Discovery Services Market for Cardiovascular Disorders, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.6 Antibody Discovery Services Market for Neurological Disorders, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 24.7 Antibody Discovery Services Market for Other Disorders, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 25.1 Antibody Discovery Services Market: Distribution by Type of Antibody
Figure 25.2 Antibody Discovery Services Market for Monoclonal Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 25.3 Antibody Discovery Services Market for Bispecific Antibodies, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 25.4 Antibody Discovery Services Market for Immunoconjugates, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.1 Antibody Discovery Services Market: Distribution by Geographical Regions
Figure 26.2 Antibody Discovery Services Market in North America, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.3 Antibody Discovery Services Market in the US, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.4 Antibody Discovery Services Market in Canada, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.5 Antibody Discovery Services Market in Europe, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.6 Antibody Discovery Services Market in Germany, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.7 Antibody Discovery Services Market in the UK, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.8 Antibody Discovery Services Market in France, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.9 Antibody Discovery Services Market in Italy, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.10 Antibody Discovery Services Market in Spain, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.11 Antibody Discovery Services Market in Rest of Europe, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.12 Antibody Discovery Services Market in Asia-Pacific, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.13 Antibody Discovery Services Market in China, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.14 Antibody Discovery Services Market in Japan, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.15 Antibody Discovery Services Market in India, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.16 Antibody Discovery Services Market in South Korea, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.17 Antibody Discovery Services Market in Australia, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.18 Antibody Discovery Services Market in Middle East and North Africa, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.19 Antibody Discovery Services Market in Egypt, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.20 Antibody Discovery Services Market in Israel, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.21 Antibody Discovery Services Market in Saudi Arabia, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.22 Antibody Discovery Services Market in Rest of Middle East and North Africa, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.23 Antibody Discovery Services Market in Latin America, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.24 Antibody Discovery Services Market in Brazil, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.25 Antibody Discovery Services Market in Argentina, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.26 Antibody Discovery Services Market in Mexico, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.27 Antibody Discovery Services Market in Rest of Latin America, Historical Trends (since 2020) and Forecasted Estimates (till 2035) (USD Million)
Figure 26.28 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 26.29 Market Movement Analysis: Geographical Regions
Figure 27.1 Licensing Agreements: Distribution of Financial Components
Figure 27.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 27.3 Global Antibody Discovery Technologies Market, Forecasted Estimates (till 2035) Base Scenario (USD Million)
Figure 27.4 Global Antibody Discovery Technologies / Platforms Market, Forecasted Estimates (till 2035) Conservative Scenario (USD Million)
Figure 27.5 Global Antibody Discovery Technologies / Platforms Market, Forecasted Estimates (till 2035) Optimistic Scenario (USD Million)
Figure 28.1 Antibody Discovery Technologies / Platforms Market: Distribution by Type of Antibody
Figure 28.2 Antibody Discovery Technologies / Platforms Market for Monoclonal Antibodies, Forecasted Estimates (till 2035) (USD Million)
Figure 28.3 Antibody Discovery Technologies / Platforms Market for Bispecific Antibodies, Forecasted Estimates (till 2035) (USD Million)
Figure 28.4 Antibody Discovery Technologies / Platforms Market for Antibody Drug Conjugates, Forecasted Estimates (till 2035) (USD Million)
Figure 28.5 Antibody Discovery Technologies / Platforms Market for Other Antibodies, Forecasted Estimates (till 2035) (USD Million)
Figure 29.1 Antibody Discovery Technologies / Platforms Market: Distribution by Type of End-User
Figure 29.2 Antibody Discovery Technologies / Platforms Market for In-house, Forecasted Estimates (till 2035) (USD Million)
Figure 29.3 Antibody Discovery Technologies / Platforms Market for Contract Research Organizations, Forecasted Estimates (till 2035) (USD Million)
Figure 30.1 Antibody Discovery Technologies / Platforms Market: Distribution by Geographical Regions
Figure 30.2 Antibody Discovery Technologies / Platforms Market in North America, Forecasted Estimates (till 2035) (USD Million)
Figure 30.3 Antibody Discovery Technologies / Platforms Market in the US, Forecasted Estimates (till 2035) (USD Million)
Figure 30.4 Antibody Discovery Technologies / Platforms Market in Canada, Forecasted Estimates (till 2035) (USD Million)
Figure 30.5 Antibody Discovery Technologies / Platforms Market in Europe, Forecasted Estimates (till 2035) (USD Million)
Figure 30.6 Antibody Discovery Technologies / Platforms Market in Switzerland, Forecasted Estimates (till 2035) (USD Million)
Figure 30.7 Antibody Discovery Technologies / Platforms Market in Germany, Forecasted Estimates (till 2035) (USD Million)
Figure 30.8 Antibody Discovery Technologies / Platforms Market in the UK, Forecasted Estimates (till 2035) (USD Million)
Figure 30.9 Antibody Discovery Technologies / Platforms Market in France, Forecasted Estimates (till 2035) (USD Million)
Figure 30.10 Antibody Discovery Technologies / Platforms Market in Rest of Europe, Forecasted Estimates (till 2035) (USD Million)
Figure 30.11 Antibody Discovery Technologies / Platforms Market in Asia-Pacific, Forecasted Estimates (till 2035) (USD Million)
Figure 30.12 Antibody Discovery Technologies / Platforms Market in China, Forecasted Estimates (till 2035) (USD Million)
Figure 30.13 Antibody Discovery Technologies / Platforms Market in Singapore, Forecasted Estimates ((till 2035)) (USD Million)
Figure 30.14 Antibody Discovery Technologies / Platforms Market in Japan, Forecasted Estimates (till 2035) (USD Million)
Figure 30.15 Antibody Discovery Technologies / Platforms Market in South Korea, Forecasted Estimates (till 2035) (USD Million)
Figure 30.16 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 31.1 Licensee: Expenditure and Revenues
Figure 31.2 Licensor: Expenditure and Revenues
Figure 31.3 Total Product Sales of Drug (USD Million)
Figure 31.4 Overall Cash Flow of Licensee (USD Million)
Figure 31.5 Overall Cash Flow of Licensor (USD Million)
Figure 31.6 Scenario 1: Multiple Cases of Varying Upfront and Milestone Payment
Figure 31.7 Scenario 2: Multiple Cases of Varying Upfront Payment and Sales based Royalty
Figure 31.8 Scenario 3: Multiple Cases of Varying Milestone Payment and Sales based Royalty
Figure 32.1 Keytruda: Annual Sales, Since 2020 (USD Billion)
Figure 32.2 Dupixent: Annual Sales, Since 2020 (USD Billion)
Figure 32.3 Stelara: Annual Sales, Since 2020 (USD Billion)
Figure 32.4 Skyrizi: Annual Sales, Since 2020 (USD Billion)
Figure 32.5 Darzalex: Annual Sales, Since 2020 (USD Billion)
Figure 32.6 Opdivo: Annual Sales, Since 2020 (USD Billion)
Figure 32.7 Humira: Annual Sales, Since 2020 (USD Billion)
Figure 33.1 Future Opportunities Related to Upcoming Trends in Drug Discovery
Figure 33.2 Other Demand Areas in Antibody Discovery Domain
Figure 34.1 Concluding Insights: Antibody Discovery Service Providers Market Landscape
Figure 34.2 Concluding Insights: Antibody Discovery Technology / Platform Market Landscape
Figure 34.3 Concluding Insights: Partnerships and Collaborations
Figure 34.4 Concluding Insights: Funding and Investments Analysis
Figure 34.5 Concluding Insights: Antibody Discovery Service Providers Market Forecast and Opportunity Analysis
Figure 34.6 Concluding Insights: Antibody Discovery Technologies / Platforms Market Forecast and Opportunity Analysis

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

全球抗體發現服務市場（按類型、宿主、分子、最終用戶和地區分類）- 預測至 2030 年

抗體藥物複合體契約製造市場（按類型、服務內容、有效載荷類型、連接體類型和應用）—2025-2030 年全球預測

美國抗體藥物複合體市場規模、佔有率和趨勢分析報告：按應用、技術、產品、目標和細分市場預測，2025 年至 2030 年

抗體探索市場，規模，佔有率，趨勢，產業分析報告:各方法，抗體類別，各終端用戶，各地區-2025～2034年市場預測

美國Ultomiris 製藥市場規模、佔有率、趨勢分析報告：按適應症、最終用途、分銷管道、細分市場預測，2025-2033 年

Ultomiris 藥品市場規模、佔有率、趨勢分析報告：按適應症、最終用途、分銷管道、地區、細分市場預測，2025-2030 年

抗體生產市場按產品類型、生產流程、類別、精製方法、應用、最終用戶分類－2025-2030 年全球預測

抗體藥物偶聯物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、應用、地區和競爭細分，2020-2030 年

PD-1 x VEGF/PD-L1 x VEGF 雙特異性抗體：從產業角度進行業務、產品線和競爭分析

全球抗體藥物複合體契約製造市場：市場規模、佔有率、趨勢分析（按連接體、按適應症、按地區）、按細分市場預測（2025-2030 年）

▼

FAQ

抗體發現市場 - 服務和平台:2035年前的產業趨勢和全球預測 - 抗體發現階段，各方法，性質，各抗體類型，各治療領域，各終端用戶，各地區

Antibody Discovery Market - Focus on Services and Platforms: Industry Trends and Global Forecasts, till 2035 - Distribution by Antibody Discovery Step, Method, Nature of, Type of Antibody, Therapeutic Area, End-user and Geographical Regions

抗體發現市場：概覽

初步研究概述

抗體發現服務市場上參與企業案例

目錄

章節I:報告概要

第1章 序文

第2章 調查手法

第3章 市場動態

第4章 宏觀經濟指標

章節II:定性洞察

第5章 摘要整理

第6章 簡介

第7章 抗體發現:流程與方法

章節III:競爭情形

第8章 市場形勢:抗體發現服務供應商

第9章 市場形勢:抗體發現技術/平台

第10章 企業競爭力分析

第11章 技術競爭力分析

章節IV:企業簡介

第12章 抗體發現服務提供者：北美公司簡介

第13章

第14章 抗體發現服務提供者：亞太地區公司簡介

第15章 抗體發現技術/平台供應商:北美企業簡介

第16章 抗體發現技術/平台供應商:歐洲企業簡介

章節V:市場趨勢

第17章 夥伴關係和合作

第18章 資金籌措投資分析

章節VI:市場機會分析

第19章 市場影響分析:促進因素，阻礙因素，機會，課題

第20章 全球抗體發現服務市場

第21章 抗體發現服務市場(抗體發現階段)

第22章 抗體發現服務市場(各抗體發現方法)

第23章 抗體發現服務市場(抗體的性質)

第24章 抗體發現服務市場(各治療領域)

第25章 抗體發現服務市場(各抗體類型)

第26章 抗體發現服務市場(各地區)

第27章 全球抗體發現技術/平台市場

第28章 抗體發現技術/平台市場(各抗體類型)

第29章 抗體發現技術/平台市場(各終端用戶)

第30章 抗體發現技術/平台市場(各地區)

第31章 授權契約結構

第32章 案例:熱門抗體藥物研發流程

第33章 抗體發現的未來的成長機會

章節VII:其他獨家洞察

第34章 結論

第35章 執行洞察

章節VIII:附錄

第36章 附錄I:表資料

第37章 附錄II:企業及組織的一覽

Antibody Discovery Market: Overview

Primary Research Overview

Example Players in the Antibody Discovery Services Market

TABLE OF CONTENTS

SECTION I: REPORT OVERVIEW

1. PREFACE

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. MACRO-ECONOMIC INDICATORS

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

7. ANTIBODY DISCOVERY: PROCESSES AND METHODS

SECTION III: COMPETITIVE LANDSCAPE

8. MARKET LANDSCAPE: ANTIBODY DISCOVERY SERVICE PROVIDERS

9. MARKET LANDSCAPE: ANTIBODY DISCOVERY TECHNOLOGIES / PLATFORMS

10. COMPANY COMPETITIVENESS ANALYSIS

11. TECHNOLOGY COMPETITIVENESS ANALYSIS

SECTION IV: COMPANY PROFILES

12. ANTIBODY DISCOVERY SERVICE PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA

13. ANTIBODY DISCOVERY SERVICE PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN EUROPE

14. ANTIBODY DISCOVERY SERVICE PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN ASIA-PACIFIC

15. ANTIBODY DISCOVERY TECHNOLOGY / PLATFORM PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA

16. ANTIBODY DISCOVERY TECHNOLOGY / PLATFORM PROVIDERS: COMPANY PROFILES OF PLAYERS BASED IN EUROPE

SECTION V: MARKET TRENDS

17. PARTNERSHIPS AND COLLABORATIONS

18. FUNDING AND INVESTMENT ANALYSIS

SECTION VI: MARKET OPPORTUNITY ANALYSIS

19. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

第1章序文

第2章調查手法

第3章市場動態

第4章宏觀經濟指標

第5章摘要整理

第6章簡介

第7章抗體發現:流程與方法

第8章市場形勢:抗體發現服務供應商

第9章市場形勢:抗體發現技術/平台

第10章企業競爭力分析

第11章技術競爭力分析

第12章抗體發現服務提供者：北美公司簡介

第14章抗體發現服務提供者：亞太地區公司簡介

第15章抗體發現技術/平台供應商:北美企業簡介

第16章抗體發現技術/平台供應商:歐洲企業簡介

第17章夥伴關係和合作

第18章資金籌措投資分析

第19章市場影響分析:促進因素，阻礙因素，機會，課題

第20章全球抗體發現服務市場

第21章抗體發現服務市場(抗體發現階段)

第22章抗體發現服務市場(各抗體發現方法)

第23章抗體發現服務市場(抗體的性質)

第24章抗體發現服務市場(各治療領域)

第25章抗體發現服務市場(各抗體類型)

第26章抗體發現服務市場(各地區)

第27章全球抗體發現技術/平台市場

第28章抗體發現技術/平台市場(各抗體類型)

第29章抗體發現技術/平台市場(各終端用戶)

第30章抗體發現技術/平台市場(各地區)

第31章授權契約結構

第32章案例:熱門抗體藥物研發流程

第33章抗體發現的未來的成長機會

第34章結論

第35章執行洞察

第36章附錄I:表資料

第37章附錄II:企業及組織的一覽